New oral anticoagulants for the treatment of venous thromboembolism: Understanding differences and similarities

Drugs

Volumn 74, Issue 17, 2014, Pages 2015-2032

  Dobesh, Paul P ^a   Fanikos, John ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; HEMOGLOBIN; RIVAROXABAN; ANTICOAGULANTS; BENZIMIDAZOLES; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES;

ANTICOAGULANT THERAPY; BLOOD TRANSFUSION; BODY WEIGHT; COMPRESSION ULTRASONOGRAPHY; DRUG EXPOSURE; ECHOGRAPHY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEMATOMA; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HUMAN; OUTCOME ASSESSMENT; PHLEBOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REVIEW; SECONDARY PREVENTION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STUDY DESIGN; VENOUS THROMBOEMBOLISM; ADMINISTRATION, ORAL; COMPARATIVE STUDY; HUMANS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84922079881     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0301-x     Document Type: Review

References (44)

1. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:I4-8. doi: 10.1161/01.CIR.0000078468.11849.66.
2. Stein PD, Matta F, Dalen JE. Is the campaign to prevent VTE in hospitalized patients working? Chest. 2011;139:1317-21. doi: 10.1378/chest.10-1622.
3. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21:722-7. doi: 10.1111/j.1525-1497.2006.00458.x.
4. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29:298-310. doi: 10.1161/ATVBAHA.108.182428.
5. Galioto NJ, Danley DL, Van Maanen RJ. Recurrent venous thromboembolism. Am Fam Physician. 2011;83:293-300.
6. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199-205.
7. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170:1710-6. doi: 10.1001/archinternmed.2010.367.
8. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S-94S. doi: 10.1378/chest.11-2301.
9. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159:445-53.
10. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006;113:577-82. doi: 10.1161/CIRCULATIONAHA.105.592592.
11. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126(832):e13-21. doi: 10.1016/j.amjmed.2013.02.024.
12. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007;13:475-86.
13. Fanikos J, Rao A, Seger AC, Carter D, Piazza G, Goldhaber SZ. Hospital costs of acute pulmonary embolism. Am J Med. 2013;126:127-32. doi: 10.1016/j.amjmed.2012.07.025.
14. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52. doi: 10.1056/NEJMoa0906598.
15. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764-72. doi: 10.1161/CIRCULATIONAHA.113.004450.
16. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, The EINSTEIN Investigators, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-510. doi: 10.1056/NEJMoa1007903.
17. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, The EINSTEIN-PE Investigators, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-97. doi: 10.1056/NEJMoa1113572.
18. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808. doi: 10.1056/NEJMoa1302507.
19. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, The Hokusai-VTE Investigators, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-15. doi: 10.1056/NEJMoa1306638.
20. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681-9. doi: 10.1001/jama.293.6.681.
21. Raskob G, Buller H, Prins M, Segers A, Shi M, Schwocho L, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study. J Thromb Haemost. 2013;. doi: 10.1111/jth.12230.
22. Tan M, van Rooden CJ, Westerbeek RE, Huisman MV. Diagnostic management of clinically suspected acute deep vein thrombosis. Br J Haematol. 2009;146:347-60. doi: 10.1111/j.1365-2141.2009.07732.x.
23. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest. 2006;129:192-7. doi: 10.1378/chest.129.1.192.
24. Fox JC, Bertoglio KC. Emergency physician performed ultrasound for DVT Evaluation. Thrombosis. 2011;2011:938709. doi: 10.1155/2011/938709.
25. Prandoni P, Lensing AW, Bernardi E, Villalta S, Bagatella P, Girolami A, et al. The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost. 2002;88:402-6. doi: 10.1267/THRO88030402.
26. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-4. doi: 10.1111/j.1538-7836.2005.01204.x.
27. van Gogh I, Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007;357:1094-104. doi: 10.1056/NEJMoa064247.
28. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708. doi: 10.1056/NEJMoa1207541.
29. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. doi: 10.1186/1477-9560-11-21.
30. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-18. doi: 10.1056/NEJMoa1113697.
31. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189-204. doi: 10.1200/JCO.2013.49.1118.
32. Nicolaides A, Hull RD, Fareed J. Diagnosis and anticoagulant treatment. Clin Appl Thromb Hemost. 2013;19:187-98. doi: 10.1177/1076029612474840n.
33. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-53. doi: 10.1056/NEJMoa025313.
34. Sardar P, Chatterjee S, Herzog E, Pekler G, Mushiyev S, Pastori LJ, et al. New oral anticoagulants in patients with cancer: current state of evidence. Am J Ther. 2014;. doi: 10.1097/MJT.0000000000000055.
35. The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Venous Thrombemobolism Disease, Version 2. Available at http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#vte. Accessed on Sep 11 2014.
36. Sardar P, Chatterjee S, Herzog E, Nairooz R, Mukherjee D, Halperin JL. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol. 2014;30:888-97. doi: 10.1016/j.cjca.2014.04.015.
37. McKesson Connect. Industry benchmark pricing. Available at https://connect.mckesson.com/portal/site/smo/Home/?link=tn. Accessed Sep 11 2014.
38. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-14. doi: 10.1056/NEJM198610303151801.
39. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-9. doi: 10.1056/NEJM199211193272103.
40. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-8. doi: 10.1056/NEJM197910183011602.
41. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-4. doi: 10.1056/NEJM199005033221802.
42. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959-67. doi: 10.1056/NEJMoa1114238.
43. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979-87. doi: 10.1056/NEJMoa1210384.
44. Cannon CP, Kohli P. Danger ahead: watch out for indirect comparisons! J Am Coll Cardiol. 2012;60:747-8. doi: 10.1016/j.jacc.2012.05.012.